Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 12
Phase 22
Phase 32

Trial Status

Completed3
Terminated1
Other1

Role Distribution

Principal Investigator3
Other Roles2
PI Rate60%

Activity Timeline

Clinical Trials (5)

NCT04444167Phase 1/2Completed
A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma
PrincipalinvestigatorStart date: 2020-07-07
NCT03866993Phase 3Completed
A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer
Lung Cancer Non-small Cell Stage IVSquamous Cell Lung Cancer
StudychairStart date: 2018-12-20
NCT03866980Phase 3Terminated
A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer
Lung Cancer Non-small Cell Stage IV
StudychairStart date: 2018-11-27
NCT04172571Phase 2Completed
A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma
PrincipalinvestigatorStart date: 2018-11-22

Research Network

Collaboration Network

4 collaborators·3 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Baohui Han, MD

Shanghai Chest Hospital

Related
7 trials

Shared therapeutic areas:

Lung Cancer Non-small Cell Stage IVSquamous Cell Lung Cancer

Worked with same sponsors:

AkesoAkeso Tiancheng, Inc
Collaborated on 2 trials
Similarity Score28%

Li Bai, MD

Chinese PLA General Hospital

Related
2 trials

Shared therapeutic areas:

Carcinoma, Hepatocellular

Worked with same sponsors:

AkesoAkeso Pharmaceuticals, Inc.+1 more
Collaborated on 2 trials
Similarity Score18%

Jeong Min Lee, MD

Seoul National University Hospital

Related
34 trials

Shared therapeutic areas:

Carcinoma, HepatocellularCancer of Pancreas
Similarity Score15%

Saleh K Saleh, MD

Minia University

Related
23 trials

Shared therapeutic areas:

Cancer of PancreasCarcinoma, Hepatocellular
Similarity Score15%

Ajay Goel, PhD

City of Hope Medical Center

Related
24 trials

Shared therapeutic areas:

Carcinoma, HepatocellularCancer of Pancreas
Similarity Score15%

Tim F Greten, M.D.

National Cancer Institute (NCI)

Related
22 trials

Shared therapeutic areas:

Carcinoma, HepatocellularCancer of Pancreas
Similarity Score15%

Gao-Jun Teng, MD

Zhongda Hospital

Related
14 trials

Shared therapeutic areas:

Carcinoma, HepatocellularCancer of Pancreas
Similarity Score15%

Zhenfeng Zhang, MD, PhD

Second Affiliated Hospital of Guangzhou Medical University

Related
21 trials

Shared therapeutic areas:

Carcinoma, HepatocellularCancer of Pancreas
Similarity Score15%

Lizhi Niu, PhD

Fuda Cancer Hospital

Related
31 trials

Shared therapeutic areas:

Cancer of Pancreas
Similarity Score8%

Ciro Gallo, M.D., Ph.D.

University of Campania Luigi Vanvitelli

Related
8 trials

Shared therapeutic areas:

Cancer of Pancreas
Similarity Score8%

Publications (0)

No publications found for this investigator.

Clinical Trials (5)

Showing 5 of 5 trials

NCT04444167Phase 1/2PrincipalInvestigator

A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma
Completed
NCT03866993Phase 3StudyChair

A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer

Lung Cancer Non-small Cell Stage IVSquamous Cell Lung Cancer
Completed
NCT03866980Phase 3StudyChair

A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer

Lung Cancer Non-small Cell Stage IV
Terminated
NCT04172571Phase 2PrincipalInvestigator

A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma
Completed
NCT01219192Phase 1PrincipalInvestigator

Study of M2ES in Patients With Advanced Pancreatic Cancer After Gemcitabine Treatment Failure

Pancreatic Cancer
Unknown

All 5 trials loaded